- Home
- MRCC vs AGEN Comparison
MRCC vs AGEN Comparison
Compare MRCC & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MRCC | AGEN |
|---|---|---|
| Founded | 2011 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.8M | 126.2M |
| IPO Year | 2011 | 1999 |
Fundamental Metrics
Financial Performance| Metric | MRCC | AGEN |
|---|---|---|
| Price | $4.68 | $3.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 153.7K | ★ 493.5K |
| Earning Date | 03-05-2026 | 03-16-2026 |
| Dividend Yield | ★ 7.81% | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $42,877,086.00 |
| Revenue This Year | N/A | $61.42 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.89 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $4.11 | $1.38 |
| 52 Week High | $7.92 | $7.34 |
Technical Indicators
Market Signals| Indicator | MRCC | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 36.67 | 54.72 |
| Support Level | $4.11 | $2.91 |
| Resistance Level | $6.77 | $4.72 |
| Average True Range (ATR) | 0.24 | 0.29 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 59.30 | 55.88 |
Price Performance
Historical ComparisonAbout MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).